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Abstract Background: After market approval, new serious safety issues are regularly
identified for drugs that lead to regulatory action to inform healthcare pro-
fessionals. However, the effectiveness of these safety-related regulatory ac-
tions is under question. We currently lack a comprehensive overview of the
effects of these drug safety warnings on clinical practice to resolve the debate
about their effectiveness.
Objective: The aim of this systematic review is to provide an overview of
studies that assessed the impact of safety warnings.
Study Selection: A systematic search was performed for articles assessing the
impact of Direct Healthcare Professional Communications or ‘Dear Doctor’
letters, Black Box Warnings and Public Health Advisories on clinical behav-
iour published between January 1996 and January 2010. The following
variables were extracted: publication year, country, name of the drug, safety
issue, specific safety warning (Direct Healthcare Professional Communication/
Black Box Warning/Public Health Advisory), effect (intended/unintended) of
the safety warning, outcomemeasure and study design. Papers were checked for
several quality aspects. Study data were summarized using descriptive analyses.
Results: A total of 50 articles were identified. Two articles assessed two dif-
ferent drugs and were therefore counted twice (n= 52). Thirty-three articles
described the impact of safety warnings issued for three drugs and drug
groups, i.e. third-generation oral contraceptives, cisapride and selective ser-
otonin reuptake inhibitors. The remaining 19 articles described a broad variety
of 14 drugs and drug groups. Twenty-five studies applied an interrupted time
series design, 23 a controlled or uncontrolled before/after design, and four ar-
ticles applied both. None of the articles could rule out the influence of con-
founding factors. The intended effects were reported in 18 (72%) of the 25
before/after analyses, whereas only 11 (41%) of the 27 interrupted time series
analyses reported an impact. Only two (8%) of the before/after analyses against
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11 (41%) of the interrupted time series analyses reported mixed impacts. When
unintended effects were assessed in case of selective serotonin reuptake inhibi-
tors and third-generation oral contraceptives, these were almost always present:
in 19 of 22 and 4 of 5 articles, respectively. Our review shows that safety-related
regulatory action can have some impact on clinical practice but firm con-
clusions are difficult to draw. Evidence is primarily based on three drugs and
drug groups. Almost half of the studies had inadequate before/after designs
and the heterogeneity in analyses and outcome measures hampered the re-
porting of overall effect sizes. Studies with adequate interrupted time series
design reported a more mixed impact of safety warnings than before/after
studies. Furthermore, this review shows the relevance of considering not only
the intended but also the unintended effects of safety warnings.
Conclusions: There is a clear need for further research with appropriate study
designs and statistical analyses, with more attention to confounding factors such
as media coverage, to understand the impact of safety-related regulatory action.
1. Background
Knowledge of the full benefit-risk profile of a
drug at the time of market approval is incomplete.
Pre-registration trials are limited in establishing
the full safety profile of new drugs due to, for
example, small sample size, short duration and a
homogeneous study population.[1,2] In approxi-
mately 10% of all marketed drugs, safety-related
regulatory action is required for new and serious
safety issues[3-5] leading to hospitalization, dis-
ability or even death.[6,7] With these safety warn-
ings, healthcare professionals and patients are
informed of these safety issues or even of the
possible withdrawal of the drug from the market.
Regulatory authorities and the pharmaceu-
tical industry employ several safety warnings to
inform healthcare providers of serious safety issues
of drugs.[8] The summary of product characteristics
can be updated with new safety information. Public
HealthAdvisories (US only) permit the notification
of patients and physicians of a serious safety issue
to improve selection of medication. A Black Box
Warning (US only) highlights a drug’s potential
safety issues in a framed box on the label and
the patient package inserts. A Direct Healthcare
Professional Communication (DHPC) [in the
EU] and Dear Healthcare Professional letter (in
the US) or ‘Dear Doctor’ letter (further referred
to as a DHPC) is a paper-based personalized
mailing to healthcare professionals. Finally, a
drug can be withdrawn from the market due to a
safety issue when the benefits of a drug no longer
outweigh its risks.
The effectiveness of safety warnings has been
criticized.[9,10] Previous research concluded that
safety warnings can be effective, albeit not always
and not always sufficiently.[10] Additionally, safety
warnings have resulted not only in intended, but
also in unintended effects. The safety warnings for
selective serotonin reuptake inhibitors resulted in
intended reduced prescription in the population
at risk after the identification of an increased risk
of suicidality and suicidal thoughts in children
and adolescents.[11] Unfortunately, some unintended
effects were also reported. The prescription of
selective serotonin reuptake inhibitors decreased
in adults as well,[12-14] possibly associated with
a temporal increase in suicidality in the general
population,[12] although these results have been
contradicted.[15]
The experience with selective serotonin reup-
take inhibitors indicates that several inventories
of effectiveness of safety warnings have been
performed, but with various results. The overall
effect of safety warnings is unclear. Since the
monitoring of the outcome of risk minimization
measures will become mandatory in the near
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future, such an overview is required.[16,17] To that
end, we performed a systematic review of the
effects – both intended and unintended – of safety
warnings on clinical practice. In this review, we
specifically targeted DHPCs, Black Box Warn-




A systematic search for articles published be-
tween January 1996 and January 2010 evaluating
the impact of DHPCs, Black Box Warnings and
Public Health Advisories safety-related regulatory
actions was performed in three steps. First, index
terms and free text words were identified from an
initial set of papers retrieved by random search.
Based on the terms used in these articles, we
systematically searched the online literature data-
bases MEDLINE and EMBASE for relevant
papers without any language restrictions (table I).
A second search in MEDLINE and EMBASE
was performed based on drugs with a DHPC in
the Netherlands. We added this step because
the initial analyses indicated that we were missing
relevant publications. As a third step, the in-
cluded papers’ references were checked (snow-
balling) and a first author search was performed
to search for additional relevant papers.
Two reviewers (SP/JV and PM) independently
evaluated all the papers identified for eligibility.
A first selection was based on titles and abstracts
and a second and final selection was based on
examination of each full paper. Any disagree-
ments were resolved during consensus meetings
with a third reviewer (SS).
2.2 Inclusion and Exclusion Criteria
Only randomized trials, quasi experiments
(interrupted time series and controlled or uncon-
trolled before/after studies) evaluating the impact
of DHPCs, Black Box Warnings and/or Public
Health Advisories on clinical practice were in-
cluded. In randomized trials the impact of an
intervention is assessed by comparing an inter-
vention group to a randomly assigned control
group. Both groups are exposed to the same
biases and therefore considered alike, permitting
the assessment of the causal effect of an inter-
vention. Before/after studies are used to measure
the impact of safety warnings at three or fewer
timepoints both before and after the intervention.
Interrupted time series designs have data col-
lected at multiple instances (preferably >20 data-
points) before and after an intervention, with the
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References of included papers
were hand searched
‘1st Authors’ last name
initial(s).’/au
Year [1996–2009]
a Italicized terms were adjusted according to specific drug/safety issue for which the DHPC was issued, or the author.
DHPC =Direct Healthcare Professional Communication.
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advantage that they can detect whether an inter-
vention has an effect significantly greater than
underlying secular trends.[18]
Cross-sectional articles evaluating only the sit-
uation after a safety warning were excluded since
no comparative impact could be estimated. For
example, articles only evaluating a safety warning
in cases of a withdrawal of a drug were excluded,
since clinical behaviour will change by definition
and the article would therefore cause bias. Opi-
nion articles, surveys, reviews, duplicates in dif-
ferent languages and publications of non-original
data were excluded to avoid publication bias.[19]
2.3 Data Extraction
Five reviewers (SP, JV,ME, FT and PMwork-
ing in varying pairs) systematically extracted the
following variables: publication year, country, drug
name, safety issue, effect (intended/unintended),
study design, safety warning type (DHPC/Black
Box Warning/Public Health Advisory) and out-
come measure. The Cochrane Effective Practice
and Organisation of Care Review Group (EPOC)
quality criteria for interrupted time series studies
score list was used to check the quality aspects of
the studies.[20] The same quality aspects were scored
for before/after papers, except for items that were
only applicable to interrupted time series design
studies. Again, any disagreements were resolved by
consensus or, if necessary, by a third reviewer.
The main goal of a safety warning, i.e. to mini-
mize occurrence of the issue, was defined as its in-
tended effect – for instance, to prevent prescription
to specific patient groups (e.g. selective serotonin
reuptake inhibitors to adolescents/children), to pre-
vent co-prescription in case of a drug-drug inter-
action (e.g. cisapride and macrolides increasing the
risk of QT prolongation), or to promote baseline/
follow-up laboratory tests (e.g. liver function test-
ing with troglitazone use).
Unintended effects were defined as unforeseen
or unintended – for instance, an increase in sui-
cides after the issuance of warnings restricting the
use of selective serotonin reuptake inhibitors in
children and adolescents.
The effect of a safety warning was scored on
the authors’ reports – i.e. a safety warning had an
effect, no effect or mixed effects. Mixed effects
were defined as an effect for one outcome mea-
sure but no effect for another.
2.4 Data Analysis
Data were summarized according to the follow-
ing variables: drug group, assessed impact, study
design, safety warnings type and outcome measure,
using descriptive analyses. The quality of the in-
cluded studies was scored by adding up each quality
aspect that was met. The studies were counted in
different ways for each variable:
 Drug group: if an article assessed a safety
warning for more than one drug, the article was
assigned to all relevant drugs and drug groups. In
that case the study was counted more than once.
 Assessed impact: the impact of a safety warning
was split into intended and unintended impacts.
 Study design: if one study assessed several out-
come measures with different study designs, the
result of each individual outcome measure was
attributed to the related study design. In such
cases a study designwas countedmore than once.
 Type of safety warning: in papers assessingmore
than one safety warning, the effect of each safety
warning was assessed separately. If more than
one safety warning was evaluated, but only one
overall effect was presented, the overall effect
was attributed to each individual safetywarning.
 Outcome measure: if one study assessed sev-
eral outcome measures, the impact of a safety
warning was counted for each individual out-
come measure. Consequently, when an impact
was observed on drug use but not on a more
specific outcome measure such as conducted
laboratory tests, the effect of that safety warn-
ing was categorized as a mixed effect.
3. Findings
A total of 4086 papers were identified using the
first search strategy, of which 215 papers were
selected for full-text examination resulting in the
inclusion of 34 papers for detailed analysis (figure 1).
The second step, based on the safety issues men-
tioned in 160 DHPCs issued in the Netherlands,
yielded a further five eligible papers. Snowballing
376 Piening et al.
Adis ª 2012 Springer International Publishing AG. All rights reserved. Drug Saf 2012; 35 (5)
yielded another eleven papers. In total 50 papers
were included. In two papers[21,22] two different
drugs and drug groups were assessed, therefore
each paper was counted twice in further analyses
(n = 52).
The main results of the data extraction are
shown in table II and the key variables of the
individual studies are shown in the Appendix
table S1 (see Supplemental Digital Content,
http://links.adisonline.com/DSZ/A64).
3.1 Drug Group
Three different drugs and drug groups, i.e.
third-generation oral contraceptives (increased risk
of thrombosis, published 1996–9);[43-51] cisapride
(risk of serious cardiac arrhythmias, published
2000–5);[21,23-26,52-54,60] and selective serotonin
reuptake inhibitors (risk of suicide in adolescents
and children, published 2005–9)[11-15,27-31,55,61-63,66]
accounted for 33 articles in our review (table II). The
remaining 19 papers described a broad variety of 14
different drugs and drug groups.[21,22,32-41,56-59,64,65]
3.2 Assessed Impact
An intended effect was observed in 9 of 14 ar-
ticles[11-15,27,28,30,31,42,55,61-63] in which the intended
effect of safety warnings for selective serotonin
reuptake inhibitors was assessed (figure 2). These
intended effects primarily concerned (large) de-
creases of the volume of drug use in children and
adolescents, but also improved psychiatric care
(Appendix table S1). Intended effects of a safety
warning issued for third-generation oral contra-
ceptives were assessed in six articles.[44-46,48,49,51]
In four of these six articles[44,46,49,51] strong re-
ductions in the use of third-generation oral con-
traceptives were reported and/or a shift in use
towards second-generation oral contraceptives.
The remaining two articles[45,48] reported mixed
impact; a reduction in drug use was observed
but no changes in venous thromboembolism
cases and discontinuation rates/switches were re-
ported. In the case of cisapride, 7 of 17 assessed
DHPCs[21,23,26,54,60] presented intended effects,
and 9[23-26,52,53] showed no intended effects (re-
duced drug use volume or contraindicated drug
use). One DHPC showed mixed results. While no
effect was observed for overall use of the DHPC,
an effect was observed for new users of cisa-
pride.[21] The early US DHPCs (1995 and 1996)
and the Italian 1998 DHPC lacked impact,
whereas subsequent US DHPCs (1998 onwards)
and the Dutch and New Zealand DHPCs did
achieve their intended effects (Appendix table S1).
Articles published on safety warnings issued
for the remaining drugs and drug groups reported
effects as intended to a varying degree. The three
papers assessing terfenadine safety warnings[32-34]
reported intended effects on contraindicated drug
use, except for contraindicated concomitant use
of ketaconazole, which did not decrease.[32] Two
of three troglitazone papers reported intended
increases in laboratory testing after the safety
warnings.[35,36] In the remaining publications a
decrease in filled prescriptions was observed only
for new drug users and not for all drug users,
explained by a higher sensitivity to detect changes
in prescriptions for new users.[21] The warning for
tramadol failed to achieve the intended decrease
in contraindicated drug use.[37,41]
Unintended effects were evaluated for safety
warnings issued for selective serotonin reuptake
inhibitors and third-generation oral contraceptives.
In the 12 publications addressing possible unin-
tended effects, of which four only assessed unin-
tended and no intended effects,[29,43,47,50] nearly all
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Fig. 1. Search results. DHPC =Direct Healthcare Professional
Communication.
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(19 of 22warnings)[12-14,29,55,61] and all fourwarnings
for third-generation oral contraceptives[43,47,49,50]
showed unintended effects.
3.3 Study Design
No randomized controlled trials, or controlled
before/after studies were identified that assessed the
intended or unintended impact of safety warnings.
Of those studies evaluating the intended ef-
fects, 23 papers applied an interrupted time series
design and 21 a before/after design (table II).
Four papers applied both interrupted time series
and before/after designs for different outcome
measures.[22,42,48] These articles are counted twice
with respect to our study design analysis, leading
to a total of 25 before/after and 27 interrupted
time series analyses.
Table II. Study characteristics
Key study characteristics Number of studies (N = 52) [n (%)] References
Country
USA 26 (50) 13,14,21-42
EU 19 (37) 11,15,43-59
Other 7 (13) 12,60-65
Drug or drug group
SSRIs 15 (29) 11-15,27-31,42,55,61-63
Third-gen. O.C. 9 (17) 43-51
Cisapride 9 (17) 21,23-26,52-54,60
Terfenadine 3 (6) 32-34
Troglitazone 3 (6) 21,35,36
Tramadol 2 (4) 37,41
Other 11 (21) 22,38-40,56-59,64,65
Assessed impact
Intended effect 40 (77) 11,21-28,30-41,44-46,48,51-54,56-60,62-65
Unintended effect 4 (8) 29,43,47,50
Both intended and unintended effect 8 (15) 12-15,42,49,55,61
Study design
ITS 25 (48) 13,14,21,23,25-30,33,34,37,39,40,50,55,56,58,60,62-65
BA 23 (44) 11,12,15,24,31,32,35,36,38,41,43-47,49,51-54,61
ITS and BA 4 (8) 22,42,48
Safety warning (n = 97)a
DHPC 65 (67) 11,12,15,21,23-27,29,32-39,41,43-60,62-65
BBW 15 (15) 12,14,22,27-29,31-33,38-40,62
PHA 17 (18) 12-14,28-30,42,56,61,62
Outcome measure (n =77)a
Drug use (volume) 35 (45) 11,12,12-14,21,22,28,39,40,42,44-46,48-52,55,56,60-65
CI/DDI 17 (22) 22-26,32-34,37,40,41,52-54,59
Laboratory testing 4 (5) 35,36,38,39
Spontaneous ADE reporting 2 (3) 57,58
Care 7 (9) 13,15,28,30,42,56,61
Other 12 (16) 12,15,29,31,43,45,47-49,55,56,61
a The numbers of evaluated safety warnings and outcome measures are larger than the number of included studies as several studies
evaluated more than one safety warning and/or outcome measure.
ADE =adverse drug event; BA =before/after study or ITS with less than three datapoints before or after an intervention; BBW =Black Box
Warning; CI/DDI = contraindicated use/drug-drug interaction; DHPC =Direct Healthcare Professional Communication; ITS = Interrupted Time
Series; PHA = public health advisory; SSRIs = selective serotonin reuptake inhibitors; Third-gen. O.C. = third-generation oral contraceptives.
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Overall, intended effects were reported in 29
(56%) of 52 analyses (figure 2). While only 11 (41%)
of 27 interrupted time series analyses reported an
impact, such intended effects were reported in
18 (72%) of 25 before/after analyses. Eleven (41%)
interrupted time series and two (8%) before/after
analyses reported mixed impact.
All six papers assessing the intended effects
of safety warnings on third-generation oral con-
traceptives had a before/after design (figure 2),
one paper also included an interrupted time
series analysis where no impact of the warning on
venous thromboembolism cases was reported
(Appendix table S1).[48] Seventeen interrupted
time series and 13 before/after designs were used
in the remaining studies. The nine interrupted
time series analyses for safety warnings on selec-
tive serotonin reuptake inhibitors, mainly re-
ported effects (four articles)[13,42,55,63] and mixed
effects (four articles).[14,27,28,62] The five inter-
rupted time series analyses assessing cisapride
warnings primarily reported mixed effects (three
articles)[21,23,26] for the different warnings that
were evaluated.
Unintended effects of the evaluated safety
warnings were reported in five of six analyses
for both interrupted time series and before/after
analyses.
Regarding the quality assessment of the pa-
pers, interrupted time series papers scored on
average 6.7 out of 8 quality aspects, ranging from
3 to 7 of 8 (Appendix table S1). Before/after pa-
pers had a similar average score of 4.6 of 6 quality
aspects, ranging from 3 to 5 of 6. All papers used
a reliable outcome measure. However, none of
the papers could rule out the influence of con-
founding factors such as media attention. Of the
29 analyses applying the stronger interrupted
time series design, 21 used appropriate statistics.
3.4 The Type of Safety Warning
Ninety-seven safety warnings were assessed in
the 52 articles, ranging from 1 to 8 warnings
per paper and 1 to 13 warnings per drug or
drug group (Appendix table S1). Twenty-one
papers evaluated more than one safety warn-
ing.[12,14,15,21-23,25-29,32,33,35,36,38,39,56,59,62,64] The
DHPC was the most frequently evaluated warn-
ings (65 of 97 warnings), with similar numbers of
Black Box Warnings (15) and Public Health Ad-
visories (16) evaluated (table II).
Intended effects were evaluated in 91 cases: 52
(57%) showed an impact, 24 (26%) did not and
15 (16%) had mixed effects (figure 3). In our
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Fig. 2. Study design and intended effects per drug and drug group. Panel (a) reports the effects of all included studies (n =52); panel (b) of ITS
studies only (n= 27); and (c) BA studies alone (n =25). Two papers evaluated safety-related regulatory action for two drugs and drug groups
(Wilkinson et al.,[21] Starner et al.[22]) and four papers used both ITS and BA analyses for different outcome measures (Libby et al.,[66] Farmer
et al.,[48] Starner et al. [·2][22]) and are therefore represented twice. Four articles assessed only unintended effects of safety warnings and
are therefore not reflected in this figure (Forrester.,[29] Child et al.,[43] Williams et al.,[50] Wood et al.[47]). BA= before/after study or ITS with
less than three datapoints before or after an intervention; ITS = Interrupted Time Series; SSRIs = selective serotonin reuptake inhibitors;
Third-gen. O.C. = third-generation oral contraceptives.
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Health Advisories had similar patterns of impact
as intended by the warnings, showing an effect in
56%, 57% and 61%, respectively, with no effect in
27%, 21% and 31%, respectively, or a mixed effect
in 17%, 21% and 8%, respectively.
Effects were reported for nearly all (86%) safety
warnings evaluating unintended effects but assess-
ment was limited to selective serotonin reuptake
inhibitors and third-generation oral contraceptives
(Appendix table S1). Only DHPCs were issued for
third-generation oral contraceptives, while selective
serotonin reuptake inhibitors received DHPCs,
Black BoxWarnings and Public Health Advisories.
No variation in impact was observed across the
different safety warnings.
3.5 Outcome Measures
The 52 articles in our study assessed the impact
of safety warnings for 77 outcome measures. The
majority (28) of articles assessed the intended im-
pact of warnings on clinical behaviour by evaluat-
ing overall drug use volume (Appendix table
S1).[11,12,14,15,21,22,27,28,39,40,42,44-46,48,49,51,52,55,56,60-65]
In some articles more specific drug use measures
were assessed: drug-drug interaction/contraindicated
use (16 articles),[22-26,32-34,37,40,41,52-54,59] drug use in
defined populations (adults, children, etc.) [16
articles],[11,12,14,15,27,28,31,45,48,49,51,55,61-63,66] new
users of a drug (1 article),[21] refusal of antidepres-
sant prescription (1 article),[31] or discontinuation
rates/switches (1 article).[45] Nine studies assessed
care-related outcomes such as the type of health-
care provider (e.g. general practitioner, psychia-
trist), diagnosing patterns (5 articles),[13,28,30,42,56]
and adherence to performing warning-dictated
laboratory tests (4 articles).[35,36,38,39] These papers
specifically intended to evaluate the non-drug-
treatment recommendations of a warning. Addi-
tionally, in five papers clinical outcome measures
were assessed, e.g. venous thromboembolism
cases (1 article),[48] mortality (1 article),[56] hos-
pital admissions (1 article)[56] and spontaneous
adverse drug event reports (2 articles).[57,58]
In eight studies the use of multiple outcome
measures led to mixed intended effects (Appendix
table S1).[21,28,32,39,40,45,48,56] For six of these eight
articles, impact was observed on the volume of
drug use in general but not for more specific out-
come measures such as drug use outcomes, e.g.
only new users of troglitazone,[21,40,45] healthcare
outcomes such as laboratory tests because of he-
patoxicity risks,[39,56] and clinical outcomes such
as venous thromboembolism cases in third-
generation oral contraceptives.[48,56] The remain-
ing two articles only reported the impact of safety
warnings on one of two contraindicated con-
comitantly used drugs,[32] and the impact of two of
the three assessed warnings on the volume of drug
use.[56]
The outcome measures for the unintended
effects of safety warnings were matched with the
specific message of a warning (Appendix table
S1). All three publications assessing spillover
effects (decreased drug use by the non-targeted
adult population) of the selective serotonin reup-
take inhibitor warnings reported effects.[12-14] The
outcome measures related to suicide and suicidal
thoughts (self-poisoning, suicide rates and hos-
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Fig. 3. Safety warnings and intended effects (n =86). Two papers
evaluated warnings for two drugs and drug groups (Wilkinson
et al.,[21] Starner et al.[22]) and four papers used both ITS and BA
analyses for different outcome measures (Libby et al.,[66] Farmer
et al.,[48] Starner et al. (·2)[22]), therefore represented twice. The
number of evaluated warnings is larger than the number of included
studies, as several studies evaluated more than one safety warning
(see Appendix table S1). BA= before/after study or ITS with less
than three datapoints before or after an intervention; BBW =Black
Box Warning; DHPC =Direct Healthcare Professional Communica-
tion; ITS = Interrupted Time Series; PHA =Public Health Advisory;
SRRAs = safety-related regulatory actions.
380 Piening et al.
Adis ª 2012 Springer International Publishing AG. All rights reserved. Drug Saf 2012; 35 (5)
Two articles reported increases in self-poisoning
cases;[29,55] but of three articles assessing suicide
rates,[12,15,61] one[15] reported no increase. The latter
study also found no increase in hospital admissions
for self-harm.[15] Lastly, impact was found on
health services use, as shown by a decrease in the
rate of physician visits after the safety warning.[61]
Both articles assessing abortions after a safety
warning for third-generation oral contraceptives
reported increases in the number of abortions.[43,49]
In addition, an increase in conceptions was ob-
served.[47]Moreover, a decrease in third-generation
oral contraceptive use was observed in Ireland,
although this was not in line with recommend-
ations by national authorities.[50]
4. Discussion
This systematic review provides the first over-
view of articles published on the effect of safety
warnings. We identified 52 studies that assessed
the impact of safety warnings on clinical practice.
Intended effects were found in the majority of
cases but varied between drugs and drug groups.
Unintended effects were also reported. No firm
conclusions on effect size can be drawn due to a
number of factors, including the small number of
drug groups evaluated, deficiencies in the study
design and inconsistency in outcome measures.
The available studies mainly assessed three drug
groups: selective serotonin reuptake inhibitors,
third-generation oral contraceptives and cisapride.
The focus on these drug groups is in line with the
extensive media attention that two of these safety-
related issues received. The studies included in-
dicated that the so-called ‘pill scare’ had a very
large impact, specifically in the UK[43-48] after the
UK Committee of Safety of Medicine advised
discontinuation of third-generation oral contra-
ceptive use. Consequently, the warnings resulted
in a similar impact in adjacent countries that had
taken a less rigorous approach.[50] A BBC broad-
cast[67] in the UK about self-harm and suicide re-
lated to the selective serotonin reuptake inhibitor
paroxetine caused further media attention in sev-
eral countries, which was followed by an extensive
reassessment of the benefits and risks associated
with the product group and a number of successive
regulatory actions, especially in the US.[68] The
debate about cisapride seems to have been trig-
gered by the potential preventability of prescribing
concomitant contraindicated drugs, but did not
generate as much public interest.
Data related to selective serotonin reuptake
inhibitors and third-generation oral contracep-
tives also shows that the observed impact was not
always as intended, which highlights the re-
levance of taking not only the intended but also
the unintended effects into account. Of eight se-
lective serotonin reuptake inhibitor papers eval-
uating the unintended effects of the warnings, six
identified unintended effects such as increases
in suicide rates and unintended spillover effects,
in particular decreased use of antidepressants in
adults. Unintended effects of the warnings were
also found for third-generation oral contra-
ceptives: increases in conceptions and abortion
rates were observed. The concerns surrounding
this specific safety issue caused many women to
switch to other oral contraceptives or to cease
using oral contraceptives all together.
How to present risk to the general public was
extensively discussed as a result of the ‘pill scare’.
The risk of venous thromboembolism with third-
generation oral contraceptive use was presented
as doubling. This implied a large increase in risk,
although the absolute risk of venous throm-
boembolism was still smaller than that of venous
thromboembolism during pregnancy. Afterwards,
restrictions on third-generation oral contraceptive
use were withdrawn in the UK and the wording of
the warning was adjusted.[69]
Almost half of the studies applied a before/
after design, which coupled with heterogeneity
in the analyses and outcome measures hampered
reporting of overall effect sizes of safety warn-
ings. Inclusion of before/after studies could be
considered a limitation due to their inherent meth-
odological flaws.[70] For example, with a before/
after study design it is not possible to control for
seasonal changes in drug use. However, it is sug-
gested that using a before/after design could be
valid where a comparable control group is used to
assess any differences between the groups that
could be attributed to the intervention.[71] Not-
withstanding that, all papers with before/after
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design were included in the systematic review to
provide a comprehensive overview of what had
been evaluated to date. Interrupted time series
design is the best available study design to evaluate
the impact of policy changes where it is almost
impossible to employ a control group, and it is
regarded as the ‘strongest’ quasi-experimental
study design.[72] When considering the interrupted
time series studies alone, the most apparent in-
tended effects of safety warnings were observed
in the case of terfenadine through a decrease in
contraindicated drug use. In cases of the selective
serotonin reuptake inhibitors and cisapride, the
majority of interrupted time series studies reported
mixed effects, mainly regarding the volume of drug
use.
The interpretation of results is further com-
plicated because of the assessment of different
outcome measures (e.g. drug use/contraindicated
drug use/laboratory tests/spontaneous adverse drug
event reports), different interventions (DHPCs/
Black Box Warnings/Public Health Advisories),
and the heterogeneity of analyses. However, since
the warnings can have different intentions, as-
sessing specific outcome measures regarding the
safety issue in question is a more accurate method
to detect the intended impact of a warning. For
example, where a DHPC is issued to address an
increased hepatoxicity risk, with a recommenda-
tion for testing the liver function of patients, as-
sessing the impact on laboratory tests could be
more appropriate than simply assessing drug use.
In addition, the majority of the papers included
did not assess every safety warning that was issued
for the drugs and drug groups. Sometimes, warn-
ings were preceded by or coincided with other
warnings regarding the same safety issue, and
which were not analysed in the study. This was the
case in the study by Gibbons et al.[12] in which
several warnings issued between October 2003 and
December 2006 were evaluated, although three
other warnings issued within that period (between
September and December 2005), were not as-
sessed. These other warnings may have strength-
ened the safety message, the impact of which was
assessed, and therefore have biased the results.
Similarly, several articles reported an overall effect
only, and lacked assessment of the effect by in-
dividual warnings. Therefore, our data do not allow
the drawing of conclusions about which safety
warning strategy is more effective, especially since
two-thirds of the warnings evaluated concerned
DHPCs.
A limitation of the outcome in all studies was
that none of the papers could rule out the influ-
ence of confounding factors such as media at-
tention, which could have strengthened the effect
of the safety warnings. For example, in the case of
the increased risk of suicide and suicidal thoughts
in selective serotonin reuptake inhibitor use, the
media hype that occurred could have been an
influential factor on the effect of the safety
warnings on drug use.[14,27,55]
The strength of this research was that it was ex-
tensive and comprehensive. Various search meth-
ods were used to minimize selection bias – searches
were performed without any language restric-
tions and only the first or most relevant paper
published on the same dataset was included.[19]
Furthermore, we evaluated different safety warn-
ings; papers assessing the effects of Black Box
Warnings and Public Health Advisories, which
were also commonly used to communicate safety
problems of drugs in the US, were also included
as well as DHPCs.
5. Conclusions
Our review highlights the gap in the current
knowledge on effectiveness of safety warnings and
also shows the relevance of taking not only the
intended effects but also the unintended affects
into account. There is a clear need for more re-
search to understand the impact of safety warn-
ings, using appropriate study designs and statistical
analyses. Both the intended and the anticipated
unintended effects of safety warnings should be
assessed. Not only should the impact on drug use
be evaluated, but also the impact on outcome
measures that specifically evaluate the intention of
the warning. Moreover, all individual warnings is-
sued for the drug in question should be assessed
instead of only a selection. The impact should be
reported per warning instead of an overall effect.
The interrupted time series study is the preferred
study design as it allows for greater reliability in
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assessing the impact of safety warnings in com-
parison to before/after designs.When conducting a
study with one drug or a limited selection of drugs,
confounding factors should be better described
and included in the analysis, which is possible with
advanced interrupted time series analysis methods.
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